BioPharma Resources

Drug Trial Radar · NCT00106340

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Dec 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,118 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,118

Actual

Start

Mar 2005

Primary completion

May 2008

Study completion May 20, 2008

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Mar 23, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 73 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the long term safety and effectiveness of vildagliptin, an unapproved drug, compared to that of glimepiride in lowering overall blood glucose levels when added to metformin in people with type 2 diabetes not at target blood glucose levels on metformin alone.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • vildagliptinDrug

  • glimepirideDrug

  • MetforminDrug

  • Vildagliptin matching placeboDrug

  • Glimepiride matching placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to HbA1c >8%Time frame: 2 year

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Novartis Pharmaceuticals

    East Hanover, New Jersey

  • Investigative Centers

    Nuremberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.